Penumbra Inc. stock holds near 315 dollars as growth expectations stay high

Published on 09/19/2026 at 20:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Penumbra Inc. stock trades around USD 315.79 on the New York Stock Exchange as of September 19, 2026, with a market capitalization above USD 12.3 billion. Recent data show non-GAAP EPS of 3.63 dollars over the last twelve months, up 36.47 percent year on year.

PEN, US70975L1070, Illustration mit AI erstellt.

Penumbra Inc. stock (ISIN US70975L1070) is trading around USD 315.79 on the New York Stock Exchange as of September 19, 2026, keeping the medical device specialist near levels that reflect strong growth expectations from investors.

Stock price and valuation context

According to ChartMill, the current Penumbra Inc. stock price is USD 315.79, with the price having increased 5.98% over the past month and 31.73% over the past year, based on data up to September 19, 2026.

The same overview from ChartMill reports a market capitalization of USD 12.37 billion for Penumbra Inc. as of the latest data, placing Penumbra firmly in the large-cap category within the healthcare sector.

Earnings momentum and growth expectations

Beyond the share price, recent earnings data help explain why Penumbra Inc. stock is valued at this level. Over the last trailing twelve months, Penumbra reported a non-GAAP earnings per share (EPS) of USD 3.63, and this EPS figure increased by 36.47% compared to the prior twelve-month period, according to ChartMill.

This combination of double-digit EPS growth and a rising share price underpins a valuation that already reflects a significant portion of expected future performance. In the same dataset, analysts are cited as expecting EPS growth of 32.46% for the next year and revenue growth of 15.96% for Penumbra, as shown by ChartMill.

From an investor perspective, a 36.47% increase in non-GAAP EPS over the last twelve months compared with the prior period is a key signal, because it suggests that Penumbra is converting its growth investments into earnings at a faster pace than before. The expectation of a further 32.46% EPS increase next year, alongside a projected 15.96% revenue increase, indicates that the market currently prices in continued expansion in both top-line and bottom-line metrics.

Profitability and sector comparison

Profitability levels provide another lens on Penumbra Inc. stock. A healthcare sector overview compiled by StockTitan lists Penumbra Inc. within its ranking of healthcare stocks by return on assets (ROA), assigning the company an ROA of 9.73% and a market capitalization of USD 12.56 billion.

An ROA of 9.73% means that Penumbra generated earnings equivalent to 9.73% of its asset base over the relevant period, which is relatively strong for a medical device company and supports the premium valuation implied by a share price near USD 315.79 as of September 19, 2026. When investors compare Penumbra with peers, a nearly 10% ROA combined with more than 30% share price appreciation over the past year offers a concrete frame for judging whether the current price adequately reflects the company's profitability and growth profile.

Return measures like ROA also help investors distinguish between growth that is capital intensive and growth that creates substantial value per dollar of assets. In Penumbra's case, the 9.73% ROA suggests that the company has been able to deploy its asset base efficiently in recent periods, which is an important factor when analysts project continued double-digit revenue and EPS growth.

Corporate actions backdrop and Boston Scientific link

The stock's valuation context also includes corporate action developments involving Penumbra Inc. and Boston Scientific Corporation. A corporate actions diary published by Netwealth in September 2026 describes a special meeting for shareholders of Penumbra Inc. (ticker PEN.NY) regarding a unification transaction linked to Boston Scientific.

According to the same Netwealth corporate actions diary, shareholders in Penumbra were offered a choice for each Penumbra share between receiving USD 374.00 in cash, 3.8721 Boston Scientific shares, or a combination of cash and shares in Boston Scientific, subject to a proration mechanism that allocates 73.26% of overall consideration in cash and 26.74% in stock.

The diary from Netwealth notes that key dates included a voting close of May 4, 2026, and a meeting date of May 6, 2026, with the effective date expected to be completed in 2026, subject to regulatory approvals and other customary closing conditions. For investors, the proposed mix of cash and Boston Scientific shares effectively ties Penumbra's valuation to the larger medical devices player, while also creating a benchmark of USD 374.00 per Penumbra share against which the prevailing market price around USD 315.79 can be compared.

This comparison is instructive: with Penumbra Inc. stock at approximately USD 315.79 as of September 19, 2026, the offered cash alternative of USD 374.00 per share from the special meeting documentation represents a level about 18.5% above the current trading price, based on the figures in the Netwealth diary and the ChartMill price snapshot.

Trading snapshot and investor perspective

Short-term trading data also reflect Penumbra's stability. A stock profile view referencing investor interest in similar medical device names shows Penumbra Inc. at USD 317.60, with a daily change of approximately -0.40%, in a 'people also follow' section that includes Penumbra alongside other healthcare stocks as of September 18, 2026, according to Seeking Alpha.

From a trading perspective, a modest daily move of -0.40% at USD 317.60, together with a one-month gain of 5.98% and a one-year gain of 31.73%, suggests that Penumbra Inc. stock is currently consolidating near the upper end of its recent range rather than experiencing abrupt volatility. Investors watching the stock can use these concrete percentage changes and price levels to judge whether the shares are extending their upward trend or pausing after a strong year.

For many investors, the key question is whether Penumbra's 36.47% non-GAAP EPS increase over the last twelve months and the expected 32.46% EPS growth for the next year justify a valuation near USD 315.79 per share when compared with the implied USD 374.00 cash alternative from the corporate actions documentation. The answer will depend on individual risk tolerance, views on the medical device industry, and expectations about Penumbra's ability to sustain double-digit revenue growth of 15.96% in the coming year.

Penumbra stock price as of the latest trading day

As of the latest available New York Stock Exchange data up to September 19, 2026, Penumbra Inc. stock is quoted at USD 315.79, with a one-month performance of 5.98% and a one-year performance of 31.73%. This level remains below the USD 374.00 cash consideration referenced in the special meeting documentation, yet above the prices seen a year earlier, reflecting both strong historical gains and the market's ongoing assessment of Penumbra's growth and profitability profile.